Adopting an IV workflow management system (IV-WMS) helps pharmacies mitigate risk by allowing them to detect drug compounding errors before they reach the patient, potentially saving lives. As of 2020, 33% of hospital pharmacies have adopted IV workflow automation, a significant increase from only 8% of pharmacies in[...]
ConsortiEX is proud to announce T3 verification, the newest feature to be added to our DSCSA Compliance as a Service (CaaS) module. The T3 Verification process gives pharmacies maximum visibility to all T3 transactions, both electronic and paper, received by their pharmacy.
The FDA released a finalized questions and answers guidance on data integrity compliance. The FDA guidance adheres to requirements under current good manufacturing practice ( cGMP) for drugs and biologics.
The FDA has issued a guidance to 503B facilities regarding Current Good Manufacturing Practice (gCMB)
Understanding the rules and regulations behind DSCSA Compliance can be a daunting task. As deadlines pass, the FDA regularly updates what it means to be compliant. ConsortiEX is proud to offer DSCSA Compliance as a Service (CaaS). Our CaaS module removes the burden of being compliant from the dispenser community with[...]
Introducing InsightRX Passive Audit Monitoring: See what others miss.
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]
We want to thank everybody who came to visit our booth at this year’s ASHP Summer Meetings & Exhibition.